Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bluebird Bio (NQ: BLUE )

0.8950 -0.0250 (-2.72%)
Streaming Delayed Price Updated: 1:21 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bluebird Bio

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Is Bluebird Bio Stock a Buy?
This small biotech is struggling to fly -- and investors should probably steer clear. 
Via The Motley Fool
Better Buy: Bluebird Bio Vs. Novavax
Who wins this face-to-face between two beaten-down biotechs? 
Via The Motley Fool
Is This Beaten-Down Stock a Good Acquisition Target?
This company has proven its innovative abilities, but that's not enough to outperform the market. 
Via The Motley Fool
Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst
Biotech stocks are famously volatile. One analyst feels this one could be volatile enough to produce an outsized gain. 
Via The Motley Fool
Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's Why
The company is working to launch its Vertex-partnered gene-editing drug for sickle cell disease and beta thalassemia. 
Via Investor's Business Daily
Peeling Back The Layers: Exploring bluebird bio Through Analyst Insights
Via Benzinga
Peering Into bluebird bio's Recent Short Interest
Via Benzinga
Is Bluebird Bio Stock a Buy Now?
Are you feeling brave? 
Via The Motley Fool
Forecasting The Future: 6 Analyst Projections For bluebird bio
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Earnings Scheduled For March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. 
Via Benzinga
Why Bluebird Bio Stock Flew Higher Than the Market Today
The company was thrown a financial lifeline. 
Via The Motley Fool
(BLUE) - Analyzing bluebird bio's Short Interest
Via Benzinga
Why Bluebird Bio Stock Dived Into the Red on Tuesday
The biotech has had a tough time of it over the past few years; a pundit's revised take on the company won't improve that situation. 
Via The Motley Fool
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results. 
Via Benzinga
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
Both companies are working on treatments for genetic disorders. 
Via Investor's Business Daily
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
Via Benzinga
If You Invested $1,000 in Bluebird Bio in 2019, This Is How Much You Would Have Today
The answer hardly inspires confidence. 
Via The Motley Fool
Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule
FDA approves CRISPR Therapeutics/Vertex's Casgevy a gene-edited cell therapy for transfusion-dependent beta-thalassemia. Vertex's swift launch strategy targets a network of treatment centers across the... 
Via Benzinga
Exposures Product Safety
2 Red Flags for Bluebird Bio Stock
The biotech's struggles may continue. 
Via The Motley Fool
Better Risky Investment: Bluebird Bio vs. Shiba Inu
Few investors dare to tread where the ice is known to be very thin. 
Via The Motley Fool
Should You Invest in Bluebird Bio Right Now?
After two December share price crashes, there's no evident cure for Bluebird Bio's ills. 
Via The Motley Fool
If You Invested $10,000 in Bluebird Bio In 2021, This Is How Much You Would Have Today
Can things get better for this struggling stock? 
Via The Motley Fool
1 Green Flag and 1 Red Flag for Bluebird Bio Stock
The stock has been in the news lately. 
Via The Motley Fool
3 Money-Saving Tricks for Investing in Biotech Stocks in 2024
Doing a little math and doing a little extra research can make a big difference. 
Via The Motley Fool
Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?
The FDA's recent approval of CRISPR Therapeutics' first therapy is a step in the right direction. 
Via The Motley Fool
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
S&P 500 Edges Lower; General Mills Cuts Sales Forecast
U.S. stocks traded mixed toward the end of trading, with the S&P 500 turning lower on Wednesday. The Dow traded up 0.07% to 37,586.02 while the NASDAQ rose 0.17% to 15,029.36. The S&P 500, however,... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Steelcase Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Steelcase Inc. (NYSE: SCS) shares moved higher during Wednesday's session following quarterly results. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.